Experimental drug for lung disease fails to reach goal

NCT ID NCT04396366

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called QBW251 in 42 adults with bronchiectasis, a lung condition that causes mucus buildup and infections. The goal was to see if the drug could reduce bacteria in the lungs and improve symptoms like coughing and breathing. However, the study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHIECTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHIECTASIS

Contacts and locations

Locations

Novartis Investigative Site

Guangzhou, Guangdong, 510120, China
Novartis Investigative Site

Shanghai, 200433, China
Novartis Investigative Site

Frankfurt, 60596, Germany
Novartis Investigative Site

Hanover, 30625, Germany
Novartis Investigative Site

Mainz, 55128, Germany
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site

Girona, Catalonia, 17007, Spain
Novartis Investigative Site

Leeds, West Yorkshire, LS9 7TF, United Kingdom
Novartis Investigative Site

Cambridge, CB2 0AY, United Kingdom
Novartis Investigative Site

Edinburgh, EH10 5HF, United Kingdom
Novartis Investigative Site

Liverpool, L7 8XP, United Kingdom
Novartis Investigative Site

Liverpool, L9 7AL, United Kingdom
Novartis Investigative Site

London, SW3 6PH, United Kingdom
Novartis Investigative Site

Manchester, M23 9LT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.